Although further testing is needed to validate findings in other cellular backgrounds and in pre-clinical studies, our data do suggest that the future development of clinically applicable PARG inhibitors may hold promise for treatment of some types of HRR-deficient tumours. This evidence concerns the gene PARG and neoplasm.